Phase II trial of docetaxel with rapid androgen cycling for progressive noncastrate prostate cancer
about
Advances in hormonal therapies for hormone naïve and castration-resistant prostate cancers with or without previous chemotherapyExploiting Epigenetic Alterations in Prostate Cancer.Efficacy and safety of docetaxel plus prednisolone chemotherapy for metastatic hormone-refractory prostate adenocarcinoma: single institutional study in Korea.Castration-dependent pharmacokinetics of docetaxel in patients with prostate cancer.Phase 1 trial of high-dose exogenous testosterone in patients with castration-resistant metastatic prostate cancer.Starving the addiction: new opportunities for durable suppression of AR signaling in prostate cancer.Uptake carriers and oncology drug safety.Use of testosterone replacement therapy in patients with prostate cancer.Beyond castration-defining future directions in the hormonal treatment of prostate cancer.Toxicity in patients receiving adjuvant docetaxel + hormonal treatment after radical radiotherapy for intermediate or high-risk prostate cancer: a preplanned safety report of the SPCG-13 trial.The change of PSA doubling time and its association with disease progression in patients with biochemically relapsed prostate cancer treated with intermittent androgen deprivation.A Pilot Study of a Multimodal Treatment Paradigm to Accelerate Drug Evaluations in Early-stage Metastatic Prostate Cancer.Beefing up prostate cancer therapy with performance-enhancing (anti-) steroids.Deletion of tumor suppressors adenomatous polyposis coli and Smad4 in murine luminal epithelial cells causes invasive prostate cancer and loss of androgen receptor expression.Drug development for noncastrate prostate cancer in a changed therapeutic landscape.
P2860
Q28829239-CFAC28D2-6B61-46D4-8915-E0B0BC02B710Q33755160-BA7EE5A2-4659-46BB-82A4-44DFE0E365EFQ33766472-E943CA8B-CBC1-490D-9D01-F798D5029AC9Q34281216-48914C98-616D-46E5-A842-1F1254378E11Q37335448-9C4ABAC0-7D52-475F-9766-0627BC6365F7Q37564765-1BDEE51F-5B81-4D7D-8626-1915D4A5BB32Q37663396-BA9932CF-637E-477F-9C2F-B865A48EC9FAQ37848698-428440E3-051C-4B75-B263-A15DDE92D15AQ37962393-557D50FD-0DFA-410A-9814-9E7AE5B2DBA3Q38472303-67939E84-D279-464B-8731-CBA4CF142C40Q38594174-E31ABB28-0F70-4471-BF67-8501674C4D74Q40456879-B9AEA819-4832-4D83-B877-EEA3C7BA3864Q42095352-CC8E3C1C-DC33-4C62-B486-2C6398959269Q47097550-A7273990-DABC-46C5-B5C8-03E09E929137Q48629219-EE982C0B-39C3-4DFB-8292-B513ED06DCC7
P2860
Phase II trial of docetaxel with rapid androgen cycling for progressive noncastrate prostate cancer
description
2008 nî lūn-bûn
@nan
2008 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2008 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
name
Phase II trial of docetaxel wi ...... ve noncastrate prostate cancer
@ast
Phase II trial of docetaxel wi ...... ve noncastrate prostate cancer
@en
Phase II trial of docetaxel wi ...... ve noncastrate prostate cancer
@nl
type
label
Phase II trial of docetaxel wi ...... ve noncastrate prostate cancer
@ast
Phase II trial of docetaxel wi ...... ve noncastrate prostate cancer
@en
Phase II trial of docetaxel wi ...... ve noncastrate prostate cancer
@nl
prefLabel
Phase II trial of docetaxel wi ...... ve noncastrate prostate cancer
@ast
Phase II trial of docetaxel wi ...... ve noncastrate prostate cancer
@en
Phase II trial of docetaxel wi ...... ve noncastrate prostate cancer
@nl
P2093
P2860
P50
P356
P1476
Phase II trial of docetaxel wi ...... ve noncastrate prostate cancer
@en
P2093
Connie Collins
Glenn Heller
Howard I Scher
Mario A Eisenberger
Martin Fleisher
Melinda Halter
Michael A Carducci
Moshe Kelsen
Roberto Pili
Samuel R Denmeade
P2860
P304
P356
10.1200/JCO.2007.15.1928
P407
P577
2008-06-01T00:00:00Z